AM1476 - A Phase I, Double-blind, Placebo-controlled, Single- and Multiple-oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects
Latest Information Update: 06 Aug 2024
Price :
$35 *
At a glance
- Drugs AM 1476 (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions; First in man
- Sponsors AnaMar AB
- 23 May 2023 Results presented in a AnaMar Media release.
- 15 Feb 2022 Status changed from recruiting to completed.
- 04 Jan 2021 New trial record